Cardiology
Sustained Benefits of Vutrisiran in Transthyretin Amyloidosis-Associated Cardiomyopathy: Insights From the HELIOS-B Open-Label Extension
Long-term treatment with vutrisiran provides sustained improvements in mortality, cardiovascular events, cardiac biomarkers, functional capacity, and quality of life in patients with transthyretin amyloidosis cardiomyopathy, emphasizing the


